Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Multi-Center Observational Study to Assess Effectiveness of Venclexta (Venetoclax) in Acute Myeloid Leukemia (AML) Patients Ineligible for Standard Induction Therapy in Routine Clinical Practice in Russian Federation (INNOVATE)

NCT04253314 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04253314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04253314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Multi-Center Observational Study to Assess Effectiveness of Venclexta (Venetoclax) in Acute Myeloid Leukemia (AML) Patients Ineligible for Standard Induction Therapy in Routine Clinical Practice in Russian Federation (INNOVATE)
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
March 13, 2020
Completion date
February 16, 2023
Enrollment
51 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml)